---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003160"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T18:37:42.370346+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protalix reports 2023 net income $8.3M vs loss; Elfabrio approvals, $20M milestone

## Summary
- Revenue from goods $40.4M (+60% YoY); license/R&D services $25.1M (+13%).
- Net income $8.3M ($0.12 diluted EPS) vs net loss $14.9M in 2022.
- Cash $44.6M at year-end; Elfabrio approved in US, EU, UK, Switzerland, Israel.
- $20M milestone from Chiesi triggered by FDA approval; $17.5M Elfabrio sales post-approval.
- PRX-115 Phase I fully enrolled; results expected Q2 2024. New chairman appointed.

## SEC filing metadata
- accession: 0001558370-24-003160
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/0001558370-24-003160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/plx-20240314x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003160
- JSON: https://secwatch.observer/filing/0001558370-24-003160.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003160.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 14, 2024, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/0001558370-24-003160-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.